AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15126920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine (100 mg/kg)
Number of subjects: 12
Study 15126920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15126920 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C (1g/day) and E (800 mg/day) for 8 consecutive days
Number of subjects: 12
Study 11790365 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone call by a pharmacist 2 days after discharge
Number of subjects: 221
Study 11790365 — intervention group
Group type: COMPARATOR
Intervention: No phone call (control group)
Number of subjects: 221
Study 11790365 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone call by a pharmacist
Number of subjects: 221
Study 9813511 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms kg‐1
Number of subjects: 6
Study 9813511 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1
Number of subjects: 6
Study 9813511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7632128 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF‐1 concentrations in patients with postpolio syndrome
Number of subjects: 87
Study 7632128 — intervention group
Group type: COMPARATOR
Intervention: Reference population comprising 392 randomly selected individuals
Number of subjects: 87
Study 7632128 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of IGF‐1 concentrations
Number of subjects: 87
Study 7632128 — intervention group
Group type: EXPERIMENTAL
Intervention: GH substitution treatment
Number of subjects: 87
Study 2198350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple stimulation with a breast pump
Number of subjects: 0
Study 2198350 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 0
Study 2198350 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple stimulation with a breast pump (failed responders switched to oxytocin)
Number of subjects: 0
Study 332439 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 mg EACH
Number of subjects: 9
Study 332439 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg EACH
Number of subjects: 9
Study 332439 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 mg EACH
Number of subjects: 9
Study 332439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31125266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin (PemCis)
Number of subjects: 0
Study 31125266 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy with etoposide-cisplatin (EtoCis)
Number of subjects: 0
Study 27577536 — intervention group
Group type: EXPERIMENTAL
Intervention: OtoTrain (web-based otoscopy simulator)
Number of subjects: 41
Study 27577536 — intervention group
Group type: COMPARATOR
Intervention: Standard otology lectures (Control group)
Number of subjects: 41
Study 27577536 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of post-test scores
Number of subjects: 41
Study 25771237 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior left atrial isolation (PLAI)
Number of subjects: 220
Study 25771237 — intervention group
Group type: COMPARATOR
Intervention: Wide antral isolation (WAI)
Number of subjects: 220
Study 23207373 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral controlled‐release morphine
Number of subjects: 10
Study 21208413 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course for insurance physicians on applying guidelines for depression
Number of subjects: 0
Study 19201775 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg/40 mg at weeks 0/2, then 40 mg every other week or weekly to week 56)
Number of subjects: 117
Study 19201775 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (open-label extension after week 56)
Number of subjects: 117
Study 19201775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 16621339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus CM
Number of subjects: 229
Study 16621339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline-only
Number of subjects: 229
Study 16621339 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus CM
Number of subjects: 229
Study 16621339 — intervention group
Group type: COMPARATOR
Intervention: Placebo-only
Number of subjects: 229
Study 16621339 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline conditions
Number of subjects: 229
Study 16621339 — intervention group
Group type: EXPERIMENTAL
Intervention: CM conditions
Number of subjects: 229
Study 12821553 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention IVUS
Number of subjects: 7484
Study 12821553 — intervention group
Group type: COMPARATOR
Intervention: Preprocedural lesion characteristics
Number of subjects: 7484
Study 10475180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous, twice daily for 3 months)
Number of subjects: 2267
Study 10475180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2267
Study 10475180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 2267
Study 8693440 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled morphine sulphate 1 mg/ml (5 ml)
Number of subjects: 10
Study 8693440 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (5 ml)
Number of subjects: 10
Study 1867418 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake extubation
Number of subjects: 70
Study 1867418 — intervention group
Group type: COMPARATOR
Intervention: Anesthetized extubation
Number of subjects: 70
Study 1867418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 6226946 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Day Hospital (ODH)
Number of subjects: 121
Study 6226946 — intervention group
Group type: COMPARATOR
Intervention: Several-Day Hospital Care (SHC)
Number of subjects: 121
Study 6226946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ODH and SHC
Number of subjects: 121
Study 4020081 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease with malnutrition
Number of subjects: 7
Study 4020081 — intervention group
Group type: COMPARATOR
Intervention: Crohn's disease without growth disturbances
Number of subjects: 7
Study 4020081 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 7
Study 4020081 — intervention group
Group type: EXPERIMENTAL
Intervention: All Crohn's disease patients
Number of subjects: 7
Study 4020081 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delayed gastric emptying
Number of subjects: 7
Study 30789463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab therapy
Number of subjects: 176
Study 29747047 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief exercise and diet advice provided during orthodontic visits
Number of subjects: 0
Study 26886857 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified cluster sampling under randomized response models
Number of subjects: 0
Study 26886857 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic sampling theories and total probability formulas
Number of subjects: 0
Study 24090685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet with soluble milk proteins (PRO)
Number of subjects: 4
Study 22729386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample sizes of a minimum of 20 for reliability
Number of subjects: 713
Study 22729386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample sizes of a minimum of 80 for validity
Number of subjects: 713
Study 20063907 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 20063907 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent systems for monitoring
Number of subjects: 0
Study 20063907 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research and case studies
Number of subjects: 0
Study 20063907 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study 18689559 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 IU/day of supplemental vitamin D(3) and 500 mg/day of supplemental calcium
Number of subjects: 257
Study 18689559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 15974900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg; two 40 mg tablets once daily)
Number of subjects: 98
Study 12873069 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Kids to Cope (TKC) program
Number of subjects: 89
Study 12873069 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 89
Study 10673791 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosine
Number of subjects: 18
Study 10673791 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 18
Study 10673791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8738693 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt position (HDT)
Number of subjects: 30
Study 8738693 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study 1761666 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF treatment with human menopausal gonadotrophin (HMG)
Number of subjects: 599
Study 1761666 — intervention group
Group type: COMPARATOR
Intervention: OHSS cases
Number of subjects: 599
Study 6121736 — intervention group
Group type: EXPERIMENTAL
Intervention: Solpadeine
Number of subjects: 74
Study 6121736 — intervention group
Group type: COMPARATOR
Intervention: DNP
Number of subjects: 74
Study 30859428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 109
Study 30859428 — intervention group
Group type: COMPARATOR
Intervention: Non-antibiotic treatment
Number of subjects: 109
Study 29607625 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric tonic, administered twice a day for 9 weeks
Number of subjects: 40
Study 29607625 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered twice a day for 9 weeks
Number of subjects: 40
Study 26780988 — intervention group
Group type: EXPERIMENTAL
Intervention: Moti-4 intervention
Number of subjects: 131
Study 25571684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum DN‐173 010 (1 x 10(10) cfu/g) in probiotic fruit yogurt, 110 g per day for 2 weeks
Number of subjects: 52
Study 25571684 — intervention group
Group type: COMPARATOR
Intervention: Placebo fruit yogurt, 110 g per day for 2 weeks
Number of subjects: 52
Study 22809258 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise training (CON)
Number of subjects: 23
Study 22809258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise training (INT)
Number of subjects: 23
Study 19358061 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 24-hour pH-monitoring
Number of subjects: 76
Study 19358061 — intervention group
Group type: COMPARATOR
Intervention: Wireless 48-hour Bravo pH-monitoring
Number of subjects: 76
Study 17439889 — intervention group
Group type: EXPERIMENTAL
Intervention: tight‐cuff cooling‐garment prototype for peripheral cooling
Number of subjects: 20
Study 17439889 — intervention group
Group type: COMPARATOR
Intervention: sham condition
Number of subjects: 20
Study 16680620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive enhancement therapy (NET) + paid work therapy (WT)
Number of subjects: 145
Study 16680620 — intervention group
Group type: COMPARATOR
Intervention: Paid work therapy (WT)
Number of subjects: 145
Study 11940541 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1.0 mg/kg subcutaneously every 12 hours +/- initial 30 mg intravenous bolus)
Number of subjects: 483
Study 11940541 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.3 to 0.75 mg/kg subcutaneously every 12 hours +/- initial intravenous bolus of 30 mg)
Number of subjects: 483
Study 11940541 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (bolus 60 U/kg; infusion 12 U/kg per hour)
Number of subjects: 483
Study 11940541 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (bolus 40 U/kg; infusion 7 U/kg per hour)
Number of subjects: 483
Study 11940541 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 483
Study 11940541 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 483
Study 10340157 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-quit group with 31-day contingency ($300 compensation for abstinence)
Number of subjects: 56
Study 10340157 — intervention group
Group type: COMPARATOR
Intervention: Delayed-quit group with 2-day contingency ($300 compensation for abstinence)
Number of subjects: 56
Study 10340157 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency duration (31 vs. 2 days)
Number of subjects: 56
Study 10340157 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher trait neuroticism, depression, and psychopathic deviate scores
Number of subjects: 56
Study 10340157 — intervention group
Group type: EXPERIMENTAL
Intervention: Prequit cotinine concentrations and Fagerström Tolerance Questionnaire scores
Number of subjects: 56
Study 8953400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (effective by electrophysiologic study)
Number of subjects: 31
Study 8953400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (ineffective by electrophysiologic study)
Number of subjects: 31
Study 8953400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (effective by Holter monitoring)
Number of subjects: 31
Study 8953400 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (ineffective by Holter monitoring)
Number of subjects: 31
Study 8953400 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (effective by both tests)
Number of subjects: 31
Study 8953400 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (effective by either test)
Number of subjects: 31
Study 8953400 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (ineffective by both tests)
Number of subjects: 31
Study 1914378 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Number of subjects: 8
Study 1914378 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg galanthamine hydrobromide intravenous infusion for 30 minutes
Number of subjects: 8
Study 1914378 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg single oral dose of galanthamine
Number of subjects: 8
Study 1914378 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro and ex vivo concentration responses
Number of subjects: 8
Study 6140230 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol (beta‐1‐selective blockade)
Number of subjects: 14
Study 6140230 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg bupranolol (nonselective beta‐blockade)
Number of subjects: 14
Study 6140230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 14
Study 6140230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beta-blockers (metoprolol and bupranolol)
Number of subjects: 14
Study 6140230 — intervention group
Group type: COMPARATOR
Intervention: Control, metoprolol, and bupranolol
Number of subjects: 14
Study 29921318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks
Number of subjects: 369
Study 29921318 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 369
Study 26299550 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2.5 mg)
Number of subjects: 90
Study 26299550 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-alfentanil combination (1 mg midazolam and 5 μg/kg alfentanil)
Number of subjects: 90
Study 26299550 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.5 mg/kg intravenous bolus)
Number of subjects: 90
Study 26299550 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 25030782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose (HF) sweetened beverage (710 mL/d, 50 g fructose/d, 15 g glucose/d)
Number of subjects: 40
Study 25030782 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose (HG) sweetened beverage (710 mL/d, 50 g glucose/d, 15 g fructose/d)
Number of subjects: 40
Study 25030782 — intervention group
Group type: COMPARATOR
Intervention: High-fructose (HF) sweetened beverage
Number of subjects: 40
Study 25030782 — intervention group
Group type: COMPARATOR
Intervention: High-glucose (HG) sweetened beverage
Number of subjects: 40
Study 22591948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal excision with lateral lymph node dissection
Number of subjects: 701
Study 22591948 — intervention group
Group type: COMPARATOR
Intervention: Mesorectal excision alone
Number of subjects: 701
Study 20033075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150-300 mg per day
Number of subjects: 901
Study 20033075 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 5-10 mg per day
Number of subjects: 901
Study 18005484 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre meal (HFM) (15 g of fibre)
Number of subjects: 10
Study 18005484 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre meal (LFM) (3 g of fibre)
Number of subjects: 10
Study 16125961 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 40
Study 16125961 — intervention group
Group type: COMPARATOR
Intervention: Endostapler
Number of subjects: 40
Study 12385542 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg orally once daily
Number of subjects: 20
Study 12385542 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg orally once daily with propranolol 40 mg orally twice daily
Number of subjects: 20
Study 9465842 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nifedipine
Number of subjects: 12
Study 9465842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9465842 — intervention group
Group type: COMPARATOR
Intervention: 2 ng/kg/min ET-1
Number of subjects: 12
Study 9465842 — intervention group
Group type: COMPARATOR
Intervention: 4 ng/kg/min ET-1
Number of subjects: 12
Study 7710436 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 7710436 — intervention group
Group type: EXPERIMENTAL
Intervention: Norverapamil
Number of subjects: 0
Study 7710436 — intervention group
Group type: COMPARATOR
Intervention: Verapamil and Norverapamil
Number of subjects: 0
Study 2696627 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin silk 8-0 suture
Number of subjects: 206
Study 2696627 — intervention group
Group type: COMPARATOR
Intervention: Interrupted nylon 9-0 suture
Number of subjects: 206
Study 2696627 — intervention group
Group type: COMPARATOR
Intervention: Double running nylon 9-0 suture
Number of subjects: 206
Study 181978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training with dietary control by dietitian counseling
Number of subjects: 60
Study 181978 — intervention group
Group type: COMPARATOR
Intervention: Exercise training without dietary control
Number of subjects: 60
Study 31200043 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 43
Study 31200043 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 43
Study 28007005 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% oral capsaicin gel
Number of subjects: 22
Study 28007005 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% oral capsaicin gel
Number of subjects: 22
Study 26093936 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole slide images and virtual microscopy adaptive tutorials
Number of subjects: 43
Study 26093936 — intervention group
Group type: COMPARATOR
Intervention: Traditional glass slide and textbook methods
Number of subjects: 43
Study 23282331 — intervention group
Group type: EXPERIMENTAL
Intervention: Malevolent beliefs about voices
Number of subjects: 31
Study 23282331 — intervention group
Group type: EXPERIMENTAL
Intervention: Benevolent beliefs about voices
Number of subjects: 31
Study 23282331 — intervention group
Group type: COMPARATOR
Intervention: General psychiatric symptoms
Number of subjects: 31
Study 23282331 — intervention group
Group type: COMPARATOR
Intervention: Frequency of voices
Number of subjects: 31
Study 23282331 — intervention group
Group type: COMPARATOR
Intervention: Perceived control of voices
Number of subjects: 31
Study 23282331 — intervention group
Group type: COMPARATOR
Intervention: Levels of depression (BDI)
Number of subjects: 31
Study 23282331 — intervention group
Group type: COMPARATOR
Intervention: Levels of anxiety (BAI)
Number of subjects: 31
Study 23282331 — intervention group
Group type: COMPARATOR
Intervention: Severity of overall psychiatric symptoms (BPRS)
Number of subjects: 31
Study 23282331 — intervention group
Group type: COMPARATOR
Intervention: Severity of negative symptoms (SANS)
Number of subjects: 31
Study 21489699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/kg CRH infusion
Number of subjects: 68
Study 19407292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 20 ml 0.5% bupivacaine (group 1)
Number of subjects: 137
Study 19407292 — intervention group
Group type: COMPARATOR
Intervention: Portal infiltration of 20 ml 0.5% bupivacaine (group 2)
Number of subjects: 137
Study 16996359 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope holder-assisted PEG placement (40 patients)
Number of subjects: 80
Study 16996359 — intervention group
Group type: COMPARATOR
Intervention: Conventional pull method of PEG (40 patients)
Number of subjects: 80
Study 12518376 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase therapy
Number of subjects: 60
Study 11063156 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 75 mg daily for 6 months
Number of subjects: 65
Study 11063156 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 9067278 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous mutation (677C‐‐>T)
Number of subjects: 202
Study 9067278 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma folate deficiency (<3 ng/ml)
Number of subjects: 202
Study 9067278 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate folate levels with homozygous mutation
Number of subjects: 202
Study 9067278 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous mutation with little or no alcohol
Number of subjects: 202